|
Mar 21
|
ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...
|
|
Mar 21
|
Q4 2024 ARS Pharmaceuticals Inc Earnings Call
|
|
Mar 20
|
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
|
|
Mar 20
|
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
|
|
Mar 20
|
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
|
|
Feb 21
|
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
|
|
Feb 18
|
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
|
|
Jan 2
|
Top US Growth Companies With Insider Ownership In January 2025
|
|
Sep 30
|
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?
|
|
Aug 27
|
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED)
|
|
Aug 26
|
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
|
|
Jul 25
|
US Growth Companies With Insider Ownership As High As 31%
|
|
Jun 26
|
US Growth Companies With High Insider Ownership To Watch
|
|
Jun 24
|
Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
|
|
May 28
|
Top US Growth Companies With High Insider Ownership To Watch In May 2024
|
|
May 13
|
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
|
|
May 11
|
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
|
|
May 9
|
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|